Zeiss Completes Acquisition of Dutch Ophthalmic Research Center (DORC)

Carl Zeiss Meditec announced it has secured all required regulatory approvals and completed the acquisition of Dutch Ophthalmic Research Center (DORC). IN December, Zeiss announced its plans to acquire from the investment firm Eurazeo SE (Paris, France) for about €985 million ($1.07 billion).

The acquisition enhances and complements Zeiss Medical Technology’s ophthalmic portfolio and its range of digitally connected workflow solutions for addressing a wide variety of eye conditions including retina and cornea disorders, as well as cataract, glaucoma, and refractive errors, according to Zeiss. 

The companies’ portfolios combine DORC’s Eva Nexus platform with Zeiss’s range of visualization, diagnostic, and therapeutic devices, and surgical instruments and consumables, which are all connected to a digital ecosystem and will enable the creation of efficient clinical workflows.

With the completion of the acquisition, the combination will provide health care professionals an extensive and unique combination of digitally connected devices and workflow solutions, from clinical preoperative needs to the surgical operating room. Immediate priorities include maintaining business continuity and customer satisfaction, cultivating areas of expertise, and enhancing the value of the companies’ solutions and services for current and future customers, stated Zeiss.